What is CMT?
Charcot-Marie-Tooth (CMT) is a genetic nerve disease with over 100 known genetic causes. Onset can be at birth or later in life and is characterized by degeneration of motor nerves and loss of sensation in the feet, hands, legs and arms. CMT is a progressive disease that can lead to severe disability or even death.
Nearly three million people of every age, race and ethnicity are living with CMT. This is the same prevalence as multiple sclerosis (MS) and ten times the prevalence of amyotrophic lateral sclerosis (ALS).
Currently there is no cure for CMT, and there are no effective treatments.
The climate for the delivery of treatments for CMT is ideal for three reasons: there is a high prevalence of people living with CMT; there are new incentives from the FDA to focus on rare, genetic diseases; and early discovery work is robust. Industry partners know these facts and are eager to deliver treatments for CMT.
The CMT Research Foundation is committed to doing our part to end CMT.
Our work is guided by three core commitments: